<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433979</url>
  </required_header>
  <id_info>
    <org_study_id>HHP-79215</org_study_id>
    <nct_id>NCT00433979</nct_id>
  </id_info>
  <brief_title>Study of Pharmacokinetics in HIV-infected Women</brief_title>
  <official_title>Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women represent an increasing proportion of HIV cases globally and in Canada, yet are&#xD;
      underrepresented in clinic trials. It is therefore critical to conduct this study on&#xD;
      antiretroviral (ARV) pharmacokinetics (PK) in women to obtain additional information on ARV&#xD;
      drug levels in women and their relation to adverse events (AEs).&#xD;
&#xD;
      The hypothesis for this study is three-fold:&#xD;
&#xD;
        1. that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our&#xD;
           female population as compared to the mean drug levels in the historical HIV population&#xD;
           (which is primarily men)&#xD;
&#xD;
        2. that ARV drug levels, particularly Cmin, are associated with body weight in women&#xD;
&#xD;
        3. that higher ARV drug levels, particularly Cmax, are associated with higher frequency and&#xD;
           severity of AEs.&#xD;
&#xD;
      The objectives of this study are as follows:&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        1. To demonstrate that levels of Protease Inhibitors (PIs) and Non-Nucleoside Reverse&#xD;
           Transcriptase Inhibitors (NNRTIs) are significantly higher in our female population as&#xD;
           compared to the mean drug levels in the historical general population (which is&#xD;
           primarily men).&#xD;
&#xD;
        2. To determine the association between PI and NNRTI minimum concentration (Cmin) and body&#xD;
           weight in our female population.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        1. To determine the association between maximum concentration (Cmax) and the frequency and&#xD;
           severity of AEs as measured by the proportion of patients with grade 2 or higher&#xD;
           laboratory or clinical AEs and the Symptom Index Score in women.&#xD;
&#xD;
        2. To determine the association between ARV drug levels and age, race, height, body mass&#xD;
           index, adherence, hormonal levels and therapy, menstruation history, duration of HIV&#xD;
           infection, duration on ARV therapy, baseline viral load, baseline CD4 count, present CD4&#xD;
           count, hepatitis B or C infection, class of ARVs, presence of ritonavir and other&#xD;
           medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Predictors of antiretroviral pharmacokinetics in HIV-infected women with virologic&#xD;
      suppression on combination antiretroviral therapy&#xD;
&#xD;
      Background&#xD;
&#xD;
      Women in Canada constitute the fastest growing population groups at risk for infection with&#xD;
      HIV and AIDS. Women now represent approximately 40% of all AIDS cases worldwide and&#xD;
      approximately 20% of cases in Canada. Although the AIDS epidemic has been ongoing for more&#xD;
      than 20 years, surprisingly little is known about the differential efficacy and toxicity of&#xD;
      various antiretroviral (ARV) drugs in women as compared to men. This gap in knowledge is a&#xD;
      result of the initial exclusion of and continued underrepresentation of women in ARV clinical&#xD;
      trials. Many studies suggest that HIV-infected women taking ARV treatment (ART) have more&#xD;
      adverse events (AEs) than men, especially in relationship to systemic symptoms like diarrhea,&#xD;
      as well as organ toxicity, including hepatotoxicity, lactic acidosis, peripheral neuropathy&#xD;
      and, notably, lipodystrophy. Currently, the occurrence and management of AEs is the most&#xD;
      important issue in the treatment of HIV. Understanding the reasons for the differences of AEs&#xD;
      in HIV-infected women is critical and has yet to be evaluated within a large cohort. It is&#xD;
      unknown whether these differences relate to hormonal influences, drug metabolism, adherence,&#xD;
      fat distribution, body size or other factors. Some small studies have found that drug levels&#xD;
      (e.g. Cmin, Cmax, AUC) are higher in women and are associated with increased toxicity.&#xD;
      Ultimately, we plan to conduct a randomized clinical trial (RCT) to assess the utility of&#xD;
      therapeutic drug monitoring (TDM) and ARV drug dose adjustment on the frequency of AEs in&#xD;
      women. Prior to conducting this RCT, it is critical to conduct this study on ARV&#xD;
      pharmacokinetics (PK) in women to obtain additional information on ARV drug levels in women&#xD;
      and their relation to AEs.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      The hypothesis for this study is three-fold:&#xD;
&#xD;
        1. that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our&#xD;
           female population as compared to the mean drug levels in the historical HIV population&#xD;
           (which is primarily men)&#xD;
&#xD;
        2. that ARV drug levels, particularly Cmin, are associated with body weight in women&#xD;
&#xD;
        3. that higher ARV drug levels, particularly Cmax, are associated with higher frequency and&#xD;
           severity of AEs.&#xD;
&#xD;
      Patient population&#xD;
&#xD;
      Eighty HIV-infected women from 8 Canadian sites who have been on their first combination ART&#xD;
      regimen containing either a PI or an NNRTI (since these are the ARV agents eligible for PK&#xD;
      analysis) for at least three months and who have evidence of full virologic suppression (HIV&#xD;
      RNA VL less than 50 copies/mL) on at least two occasions at least one month apart.&#xD;
&#xD;
      Objectives Primary objectives&#xD;
&#xD;
        1. To demonstrate that the Cmin and Cmax of PIs and NNRTIs are significantly higher in our&#xD;
           female population as compared to the mean drug levels in the historical general&#xD;
           population (which is primarily men).&#xD;
&#xD;
        2. To determine the association between PI and NNRTI Cmin and body weight in our female&#xD;
           population.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        1. To determine the association between Cmax and the frequency and severity of AEs as&#xD;
           measured by the proportion of patients with grade 2 or higher laboratory or clinical AEs&#xD;
           and the Symptom index score in women.&#xD;
&#xD;
        2. To determine the association between ARV drug levels and age, race, height, body mass&#xD;
           index, adherence, hormonal levels and therapy, menstruation history, duration of HIV&#xD;
           infection, duration on ARV therapy, baseline VL, baseline CD4 count, present CD4 count,&#xD;
           hepatitis B or C infection, class of ARVs, presence of ritonavir and other medications.&#xD;
&#xD;
      Study design&#xD;
&#xD;
      The study will be a cross-sectional study with ARV drug levels (Cmin and Cmax) measured&#xD;
      weekly for three weeks Three samples will be taken from each subject to reduce variability&#xD;
      due to both technologic and biologic sources. Data will be collected on demographic&#xD;
      characteristics, clinical disease and ARV history and on clinical toxicities at the first&#xD;
      visit. Blood work will be carried out on the first visit to assess for laboratory toxicity&#xD;
      and hormonal levels.&#xD;
&#xD;
      Data analysis&#xD;
&#xD;
      Drug levels will be summarized with the mean of the 3 values for Cmin and Cmax for each woman&#xD;
      for their PI or NNRTI and compared to the mean values of the general HIV population. Cmin and&#xD;
      Cmax will be classified into high and low levels with a high level defined as less than or&#xD;
      equal to 1.5 X arithmetic population mean for each drug. Characteristics of patients with&#xD;
      high drug levels will be compared to those of patients with low drug levels. Univariate and&#xD;
      multivariate logistic regression models will be used to identify independent associations of&#xD;
      patient characteristics with high drug levels. The proportions of patients with AEs and the&#xD;
      median number of AEs per patient will be compared between patients with high Cmax and&#xD;
      patients with low Cmax.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">88</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiretroviral treatment</intervention_name>
    <description>These antiretroviral drugs are a part of the participant's current drug regimen.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be drawn before and after antiretroviral drugs are taken for visits 1-3.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will consist of 80 HIV-infected women (who are on their first cART&#xD;
        regimen containing either a PI or an NNRTI for at least three months and who have evidence&#xD;
        of full virologic suppression (HIV RNA VL &lt; 50 copies/mL) on at least two occasions at&#xD;
        least one month apart. The first cART regimen can include ARV switches as long as these&#xD;
        switches are not due to virologic failure. The patient population is being limited to women&#xD;
        who have full virologic suppression to avoid inclusion of women with difficulty with drug&#xD;
        adherence.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be HIV infected&#xD;
&#xD;
          -  Patient must be 18 years old or older&#xD;
&#xD;
          -  Patient must be a biologic woman&#xD;
&#xD;
          -  Patient must be taking her first combination ARV regimen that includes a PI or an&#xD;
             NNRTI for the past three months with no changes in any agent of the combination in&#xD;
             that period (first combination ARV regimen is defined as a regimen started when the&#xD;
             patient was ARV-na√Øve; however switches are allowed as long as the switches are not&#xD;
             for virologic failure)&#xD;
&#xD;
          -  Patient must be taking either a PI or an NNRTI but not both&#xD;
&#xD;
          -  If taking a PI, patient must be taking only one PI excluding low dose ritonavir used&#xD;
             as boosting&#xD;
&#xD;
          -  Patient must have a viral load &lt; 50 copies/mL on two occasions at least 1 month apart&#xD;
             including a value within three months before the baseline visit&#xD;
&#xD;
          -  Patient has to have signed and dated a full informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who would have difficulty participating in a trial due to non-adherence or&#xD;
             substance abuse&#xD;
&#xD;
          -  Patient who is pregnant or breast-feeding&#xD;
&#xD;
          -  Patient with a malignancy receiving systemic chemotherapy&#xD;
&#xD;
          -  Patient with end stage organ disease&#xD;
&#xD;
          -  Patient with other significant non-HIV underlying disease that might impinge upon&#xD;
             disease progression or death&#xD;
&#xD;
          -  Patient who is not taking standard dosing of a PI or NNRTI as listed in Appendix G&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona R Loutfy, MD FRCPC MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children and Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Infectious Diseases Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Health Services</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1N 6N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Immunodeficiency Research Collaborative</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Hospital HIV Care Program</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du Centre hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuq/Chul</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Mona Loutfy</name_title>
    <organization>Women's College Research Institute</organization>
  </responsible_party>
  <keyword>Anti-HIV agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>ARV-associated Adverse Events</keyword>
  <keyword>HAART</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Non-nucleoside Reverse Transcriptase Inhibitors</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

